Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study
NCT ID: NCT01689389
Last Updated: 2015-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2292 participants
OBSERVATIONAL
2012-12-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Main study population
All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.
Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months.
No interventions assigned to this group
Schizophrenia SoC sample
Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
No interventions assigned to this group
Bipolar SoC sample
Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant \[N06A\], antipsychotic (other than Quetiapine XR) \[N05A\] or mood stabilizer (including lithium \[N05AN\], valproate \[N03AG01\], and lamotrigine \[N03AX09\].
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18 years and over
* Diagnosis of bipolar disorder or schizophrenia according to DSM-IV criteria
Exclusion Criteria
* Patient refusing to participate in the study
* Pregnant women
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruno FALISSARD, Pr
Role: PRINCIPAL_INVESTIGATOR
Paris
Pierre-Michel LLORCA, Pr
Role: PRINCIPAL_INVESTIGATOR
Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Argenteuil, , France
Research Site
Belley, , France
Research Site
Castelmaurou, , France
Reserach Site
Cavaillon, , France
Research Site
Les Mureaux, , France
Research Site
Lille, , France
Research Site
Marseille, , France
Research Site
Montpellier, , France
Research Site
Nîmes, , France
Research SIte
Obernai, , France
Research Site
Paris, , France
Research Site
Rennes, , France
research Site
Saint-Dizier, , France
Research Site
Saint-Égrève, , France
Research Site
Saintes, , France
Research Site
Sens, , France
Research Site
Toulouse, , France
Research Site
Tours, , France
Research Site
Ussel, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
NIS-NFR-SER-2012/1 SUMMARY SYNOPSIS
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-NFR-SER-2012/1
Identifier Type: -
Identifier Source: org_study_id